| 1 |
33296710 | Inhibitory effects of vandetanib on creatinine transport via renal organic cation transporter OCT2. | 2021 Mar 1 |
2 |
| 2 |
33929994 | Vandetanib-eluting radiopaque beads for chemoembolization: physicochemical evaluation and biological activity of vandetanib in hypoxia. | 2021 Oct 1 |
1 |
| 3 |
31258881 | Anti-angiogenesis triggers exosomes release from endothelial cells to promote tumor vasculogenesis. | 2019 |
2 |
| 4 |
29517106 | Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo. | 2018 May |
1 |
| 5 |
30555244 | Vandetanib (ZD6474) induces antiangiogenesis through mTOR-HIF-1 alpha-VEGF signaling axis in breast cancer cells. | 2018 |
4 |
| 6 |
28413487 | Vandetanib and ADAM inhibitors synergistically attenuate the pathological migration of EBV-infected retinal pigment epithelial cells by regulating the VEGF-mediated MAPK pathway. | 2017 Apr |
4 |
| 7 |
26715573 | Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers. | 2016 Apr |
2 |
| 8 |
26832420 | [Tyrosine kinase inhibiting the VEGF pathway and elderly people: Tolerance, pre-treatment assessment and side effects management]. | 2016 Mar |
1 |
| 9 |
27429741 | Identification of selective inhibitors of RET and comparison with current clinical candidates through development and validation of a robust screening cascade. | 2016 |
1 |
| 10 |
27983649 | Design and Synthesis of Vandetanib Derivatives Containing Nitroimidazole Groups as Tyrosine Kinase Inhibitors in Normoxia and Hypoxia. | 2016 Dec 14 |
1 |
| 11 |
25684635 | Effects of receptor tyrosine kinase inhibitors on VEGF165 a- and VEGF165 b-stimulated gene transcription in HEK-293 cells expressing human VEGFR2. | 2015 Jun |
1 |
| 12 |
26677336 | Profile of nintedanib in the treatment of solid tumors: the evidence to date. | 2015 |
1 |
| 13 |
24671507 | A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy naïve castration-resistant prostate cancer. | 2014 Aug |
1 |
| 14 |
24913066 | Vandetanib and indwelling pleural catheter for non-small-cell lung cancer with recurrent malignant pleural effusion. | 2014 Sep |
2 |
| 15 |
24924416 | Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study. | 2014 Jul |
1 |
| 16 |
22608542 | Contrasted effects of the multitarget TKi vandetanib on docetaxel-sensitive and docetaxel-resistant prostate cancer cell lines. | 2013 Nov |
1 |
| 17 |
23766359 | Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma. | 2013 Aug 1 |
1 |
| 18 |
23856028 | Recombinant leukemia inhibitory factor suppresses human medullary thyroid carcinoma cell line xenografts in mice. | 2013 Oct 1 |
1 |
| 19 |
24089699 | Specific binding of modified ZD6474 (Vandetanib) monomer and its dimer with VEGF receptor-2. | 2013 Nov 20 |
2 |
| 20 |
21095630 | Epidermal growth factor receptor expression modulates antitumor efficacy of vandetanib or cediranib combined with radiotherapy in human glioblastoma xenografts. | 2012 Jan 1 |
1 |
| 21 |
21404105 | A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer. | 2012 Jun |
2 |
| 22 |
22245891 | Vandetanib in patients with inoperable hepatocellular carcinoma: a phase II, randomized, double-blind, placebo-controlled study. | 2012 May |
1 |
| 23 |
22415301 | Myc-associated zinc finger protein (MAZ) is regulated by miR-125b and mediates VEGF-induced angiogenesis in glioblastoma. | 2012 Jun |
1 |
| 24 |
22701615 | Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer. | 2012 |
1 |
| 25 |
21106730 | Vandetanib improves anti-tumor effects of L19mTNFalpha in xenograft models of esophageal cancer. | 2011 Feb 1 |
1 |
| 26 |
21390182 | Metronomic S-1 chemotherapy and vandetanib: an efficacious and nontoxic treatment for hepatocellular carcinoma. | 2011 Mar |
3 |
| 27 |
21770481 | Vandetanib: first global approval. | 2011 Jul 9 |
2 |
| 28 |
19949019 | Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. | 2010 Jan 10 |
1 |
| 29 |
20031962 | Advances in target therapy for lung cancer. | 2010 Feb |
1 |
| 30 |
20571071 | Targeted therapies for non-small cell lung cancer: an evolving landscape. | 2010 Jul |
1 |
| 31 |
20811684 | VEGFR and EGFR inhibition increases epithelial cellular characteristics and chemotherapy sensitivity in mesenchymal bladder cancer cells. | 2010 Oct |
1 |
| 32 |
19002384 | Open-label phase I trial of vandetanib in combination with mFOLFOX6 in patients with advanced colorectal cancer. | 2009 Jun |
1 |
| 33 |
19362942 | Combined inhibition of vascular endothelial growth factor and epidermal growth factor signaling in non-small-cell lung cancer therapy. | 2009 Mar |
1 |
| 34 |
19447868 | Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer. | 2009 May 15 |
14 |
| 35 |
19519336 | Recent developments of targeted therapies in the treatment of non-small cell lung cancer. | 2009 Jun |
1 |
| 36 |
19747132 | Angiogenesis inhibitors and vascular disrupting agents in non-small cell lung cancer. | 2009 |
1 |
| 37 |
19883226 | Decrease in tumor cell oxygen consumption after treatment with vandetanib (ZACTIMA; ZD6474) and its effect on response to radiotherapy. | 2009 Nov |
1 |
| 38 |
18245671 | Potent antitumor effects of ZD6474 on neuroblastoma via dual targeting of tumor cells and tumor endothelium. | 2008 Feb |
1 |
| 39 |
18379357 | A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer. | 2008 Apr |
1 |
| 40 |
18694994 | Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells. | 2008 Aug 15 |
1 |
| 41 |
18695882 | Administration of VEGF receptor tyrosine kinase inhibitor increases VEGF production causing angiogenesis in human small-cell lung cancer xenografts. | 2008 Sep |
1 |
| 42 |
17203163 | Antitumor effects of ZD6474 on head and neck squamous cell carcinoma. | 2007 Feb |
1 |
| 43 |
17308046 | Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade. | 2007 Feb |
1 |
| 44 |
17671152 | Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancer. | 2007 Aug 1 |
2 |
| 45 |
16332356 | ZD6474 inhibits proliferation and invasion of human hepatocellular carcinoma cells. | 2006 Feb 14 |
2 |
| 46 |
16377413 | ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinase activity in combination with radiotherapy. | 2006 Jan 1 |
1 |
| 47 |
16640800 | Emerging antiangiogenic agents in lung cancer. | 2006 Mar |
1 |
| 48 |
17145834 | Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer. | 2006 Dec 1 |
1 |
| 49 |
15655420 | New drugs in cancer therapy, National Tumor Institute, Naples, 17-18 June 2004. | 2005 Feb |
1 |
| 50 |
15905307 | Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. | 2005 Aug |
1 |